MDT perspectives on tracking prognostic and predictive biomarkers for immunotherapy

touchMDT for touchONCOLOGY Listen to key experts from a multidisciplinary team discuss the tools used to predict response to immunotherapy, and they review emerging biomarkers. The multidisciplinary team: Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/